

Dr. med. Ralph Link

A list of published papers:

1. Immunogenicity of synthetic oligopeptides corresponding to epitopes of Friends murine leukemia virus glycoprotein covalently linked to lipopeptides.
Ralph Link, T. Böltz et al.
Immunobiol. 178; 64.
2. Histopathological Studies on the local reactions induced by complete Freund's Adjuvant (CFA), bacterial Lipopolysaccharide (LPS), and synthetic Lipopeptide (P3C) Conjugates.
Frank Wiedemann, Ralph Link et al.
Journal of Pathology, Vol. 164:265-271(1991)
3. Immunogenität synthetischer F-MuLV- und HIV-Oligopeptid-Lipopeptid-Konjugate in BALB/c- und STU-Mäusen.
W. Bessler, R. Link et al.
Abstract, 2. Deutscher AIDS-Kongress, Berlin, FRG.
4. Safety and Tolerability of Peginterferon Alpha-2A (40KD)(PEGASYS) Monotherapy and combination Therapy with Ribavirin (COPEGUS) in Patients with chronic Hepatitis C: Results of a German, Multicenter open-label trial
B. Möller, ... Ralph Link et al.
Journal of Viral Hepatitis, Volume 14, Number 11, November 2007, pp788-796(9)
5. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy
Wulf O. Böcher, ... Ralph Link et al.
Liver International 2006;26; 319-325
6. Comparison of a 24-week standard combination therapy with PEG-IFN alfa-2a/Ribavirin with a 12-week monotherapy with PEG-IFN alfa-2a followed by a 12 week standard combination with PEG-IFN alfa-2a/Ribavirin in Hepatitis C infected patients with genotyp 2 or 3.
Kallinowski Birgit, ... Link Ralph et al.
Presented at the 57 Annual Meeting of the American Ass. for the Study of Liver Diseases 2006 October 27-31; Boston; Massachusetts; USA
7. K-light chain amyloidosis of the liver, a rare cause of liver enzyme elevation
J.P. Borde, R.Link, W.B. Offensperger
Dtsch Med Wochenschrift 2008;133;116-1120
8. Estimating the Likelihood of Sustained Virological Response in Chronic Hepatitis C (CHC) Therapy
Mauss S., Hueppe D., ... Link R. et al.
Presented at the 43 Annual Meeting of the European Ass. for the Study of Liver (EASL) 2008 April 23-27; Milan, Italy
Journal of Viral Hepatitis, 2010 / j.1365-2893
9. Efficacy and Tolerability of Peginterferon alpha-2a or - 2b plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Germany: The PRACTICE Study
Witthoeft T, Hueppe D., ... Link R. et al.
Presented at the 43 Annual Meeting of the European Ass. for the Study of Liver (EASL) 2008 April 23-27; Milan, Italy

10. Comparison of the efficacy of peginterferon alfa-2a and -2b plus ribavirin in the treatment of chronic hepatitis C patients in daily routine: results from Practice
*Witthoeft Thomas, ... **Link Ralph** et al.*
AASLD Poster 2010
EASL-Abstract 2008, Mailand
11. Effektivität und Sicherheit von Escitalopram zur Prävention PEG-IFN-alpha assoziierter Depressionen bei Patienten mit chronischer Hepatitis C (CIPPAD-Studie)
*Schaefer, M.; Sarkar, R.; ...**Link, R.**: et al.*
Hepatology 2008;48(4):423A
12. Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C serotyp-1
*M. Schuchmann, H.F. Löhr, **R. Link**, et al.*
AASLD 2007
13. Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3
*F. Rahman; M. Schuchmann; H. F. Löhr; **R. Link**; P. Buggisch; et al*
AASLD 2007
14. consensus interferon/ribavirin versus peg-interferon alfa2b/ribavirin in treatment-naive Daily patients with chronic hepatitis C and serotype-2 or -3: Interim results from the PACT-trial
*W.O. Böcher, M. Fuchs, P. Buggisch, S. Kaiser, **R. Link**, et al.*
AASLD 2007
15. longterm benefits of sustained virological response (SVR) in patients with chronic hepatitis C (CHC) virus infection: The German „LOTOS STUDY“
Reimer. J., ... Link.R., et al
DDW 2011 Chicago; Posternummer 6795
16. Kostenevaluation der ärztlichen Leistung einer Behandlung der cHCV mit Peginterferon alfa-2a und Ribavirin als Beitrag zur Qualitätssicherung im Gesundheitswesen.
*S. Rossol, M. Schuchmann ... **R.Link**, et al.*
17. PEG-Interferon-alfa2a/ribavirin - phlebotomy in HCV GT 1patients – final results of the KAPRI trial.
*Erhardt, B. Möller ... **R.Link**, et al.*
18. Pathological glucose tolerance and treated hypertension identify HCV-patients with negative prognostic parameters for SVR.
*E. Jaeckel, E. Zehnter, T. Lutz, ... **R.Link**, et al.*
19. Confirmation of high SVR rates after shortening duration of treatment with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patient with RVR In Real Life.
*Stefan Mauss, **Ralph Link**, et al.*
eingereicht AASLD San Franzisco 2011
20. Pharmaeconomic Evaluation of chronic HCV Treatment with Peginterferon alfa-2a/Ribavirin-real life setting in a large German cohort of 1147 patients.
*S. Rossol, M. Schuchmann, S. Mauss ... **R.Link**, et al*
eingereicht AASLD San Franzisco 2011

21. The role of ferritin as a response marker for antiviral treatment of chronic Hepatitis C patients with Peginterferon alfa-2a (PegIFN) and Ribavirin (RBV).
*KLass D.M., Zizer E., **Link R.**, ..., et al.*
eingereicht AASLD San Francisco 2011
22. The role of weight loss (WL) as on treatment predictive Factor for SVR in the treatment of chronic Hepatitis C (CHC) patients with Peginterferon alfa-2a (PEG) and Ribavirin.
Thomas Witthoef, Klaus Boeker, ... Ralph Link, et al.
eingereicht AASLD San Francisco 2011
23. Predictive factors for nonresponse in genotype 2/3 infected chronic hepatitis C patients treated with Peginterferon alpha-2a and Ribavirin in real life setting
*J.Petersen, T. Lutz, **R. Link**, et al.*
EASL 2012 Abstract A-455-0022-00894, Barcelona, Spain
DDW 2012
24. Viral response at week 2 as a predictive factor for RVR in chronic HCV Genotyp 1 Infection treated with Peginterferon-alpha-2a and Ribavirin
*S. Mauss; T.Lutz; K.Boeker; **R. Link**; et al.*
EASL 2012 Abstract A-455-0022-0084, Barcelona, Spain
DDW 2012
25. Early markers of metabolic syndrome are associated with distinct HCV genotypes, while abnormal glucose tolerance substantially decreases the likelihood of SVR
E. Jaeckel, E. Zehnter, T. Lutz, A.Carlebach, R. Link et al.
EASL 2012 Abstract, Barcelona, Spain
26. Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotyp 1 infection and elevated GGT levels.
*A.Böhig, V.Weich, ... **Ralph Link**; et al.*
WORDS Abstract 350
27. Starke Assoziation von Markern des metabolischen Syndroms mit HCV Genotyp 1,4,5 und schlechtes Therapieansprechen bei Patienten mit gestörter Glucosetoleranz.
*E. Jaeckel, E. Zehnter, **R. Link**; et al.*
EASL 2012 Abstract
28. Patient Adherence: The influence of non-virological factors in a real world setting
*T. Witthöft, **R. Link**; et al.*
DGVS 2012
29. Clinical Presentation of Chronic Liver Disease in Germany: Role of Etiology, Age and Gender,
*A. Tromm, J. Petersen, P. Buggisch, S. Holm, **R. Link**; et al.*
DGVS 2012,
30. Factors associated with rapid virological response (RVR) in the treatment of chronic hepatitis C (cHC) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in patients with and without opioid substitution treatment (OST)
*Jens Reimer; Bernd Weber; ... **Ralph Link**; et al.*
Abstract AASLD 2012, Boston, Massachusetts (1420283)
31. Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients
*Martin Schaefer, MD; ... **Ralph Link**, MD; et al.*
Abstract JAMA 10-7938

32. Epidemiologie, Behandlungsergebnisse und Kosten der Behandlung chronischer HCV-Patienten in Deutschland – Ergebnisse einer großen Multicenter Studie.
Rossol S; Stahmeyer J.T.; Bert F; Mauss S; Link R; et al.
Konferenz Viszeralmedizin 2013 Abstract A-592-0004-00323
33. Gründe zur Ablehnung einer Hepatitis C Therapie vor dem Hintergrund neuer Therapieoptionen.
Mauss S.;Stoehr A.;Schober A.;Holm S.; Beoker K.H.W.; Link R.; et al.
Z.Gastro 44(8), 797 Abstr. P275 (2006), Kongress Viszeralmedizin 2013 (DGVS)
34. Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt?
Hueppe D.; Mauss S.; ... Link R.; Moog G.; et al.
eingereicht Kongress Viszeralmedizin 2013 (DGVS)
35. Real world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alpha-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study
Peter Buggisch, Andreas Schober; ... Ralph Link et al.
AASLD-The Liver Meeting 2013, Washington,DC
36. 24 week treatment of former relapse, HCV genotyp 1 infected patients with telaprevir in combination with peginterferon alpha 2a/ribavirin-experiences under real life conditions
Klaus H. Boeker; Ralph Link et al.
AASLD-The Liver Meeting 2013, Washington,DC
37. Baseline characteristics and treatment response of HCV genotyp 1 patients with previous null response that are retreated with TVR or BOC triple therapy in real world setting
Wolf P.Hofmann, Stefan Mauss; ... Ralph Link; ... et al
AASLD-The Liver Meeting 2013, Washington,DC
38. Patient Adherence: the Influence of Non-virological Factors in a Real word Setting
Thomas Witthoeft, Ralph Link, et al.
APASL 2013 abstract
39. Quality of Life Profiles in Patients in Contact with the Hepatitis C Virus
Reimer J; Hueppe D; ... Link R; ... et al.
3rd Intern. Symposium on Hepatitis Care in Substance Users (INHSU 2013); Munich
40. Baseline Characteristics and Treatment Response of HCV Genotyp 1 Patients with Previous Null Response That Are Retreated with TVR or BOC Triple Therapy in Real World Setting
Hofmann WP;Mauss S; Baumgarten A; Boeker KH; Link R; ... et al.
AASLD-The Liver Meeting 2013, Washington,DC, USA
41. Overtreatment of Patients with chronic Hepatitis C (cHC) Genotyp 2/3 with low baseline viral load and RVR: Experiences in a real world setting
B.Heinrich; St. Wiegand; J.Petersen; H.Hinrichsen; Ralph. Link; et al.
AASLD-The Liver Meeting 2013, Washington,DC, USA
42. Performance and value of IFN-Lambda 3 and IFN-Lambda 4 Genotyping in Patients with chronic Hepatitis C (cHC) Genotype 2/3 in a real world setting
St. Wiegand; B. Heinrich; S.Susser; ... ; Ralph. Link; et al.
AASLD-The Liver Meeting 2013, Washington,DC, USA
43. 24 Week Re-treatment with Telaprevir-Triple Therapy in Patients with HCV-Genotype 1 who had Relapsed after Peginterferon/Ribavirin Treatment.
Boeker KH; Link Ralph; et al.
AASLD-The Liver Meeting 2013, Washington,DC, USA

44. Safety analysis of Endoscopist-Directed Sedation. A prospective, national multicenter study of 24.441 patients in German outpatient practices
*Andreas Sieg, **Ralph Link** in bng-Study-Group, Sebastian Beck; et al.*
Gastroenterology, in process
45. Smoking does not negatively influence Interferon-based antiviral Therapy in Treatment naive, HCV Genotype 1 infected Patients
*Tim Zimmermann; Klaus.H.W. Boecker; Andreas Schober; **Ralph Link**; ... et al.*
EASL 2014, Abstract eingereicht
46. Baseline characteristics and treatment efficacy of telaprevir in combination with peginterferon alfa-2a and ribavirin in 253 HCV genotype 1 nonresponder patients in a real-world setting.
*W.P. Hofmann; S.Mauss; A.Baumgarten; K.H.W. Boecker; **R.Link** et al.*
EASL 2014, Abstract London
47. Triple therapy with boceprevir (BOC) under daily conditions: Is it possible to achieve SVR rates comparable to pivotal trials?
*Peter Buggisch; Andreas Schober; ... **Ralph Link**; et al.*
EASL 2014, Abstract London
48. Adverse Events and co-medication: a comparison between dual and triple combination therapies in genotype 1 patients with chronic hepatitis C
*Eckart Schott; Andreas Schober; **Ralph Link**; et al.*
EASL 2014, Abstract London
49. Sustained virological response (SVR) in HCV treatment-experienced patients after triple therapy with boceprevir (BOC) plus peginterferon alfa-2a / ribavirin in a real-life setting.
*Klaus H.W. Boecker; **Ralph Link**, Axel Baumgarten; et al.*
EASL 2014, London
50. Non-virological factors predicting patient adherence during antiviral treatment of genotype 1/4 infection in real world: role of gender and age
*Thomas Witthoeft; **Ralph Link**; Stefan Christensen; et al.*
Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington
51. *Baseline characteristics and treatment response of HCV genotype 1 patients with previous null response that are retreated with TVR or BOC triple therapy in real world setting*
*Wolf P. Hofmann; Stefan Mauss; Axel Baumgarten; Klaus H. Boeker; **Ralph Link**; et al.*
Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington
52. 24 week treatment of former relapse, HCV genotype 1 infected patients with telaprevir in combination with peginterferon alfa 2a/ribavirin – experiences under real life conditions
*Klaus H. Boeker; **Ralph Link**; et al*
Hepatology, Volume 58, Number 4; AASLD Abstract 2013 in Washington
53. Treatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: Relevance for the new era of DAA
*Benjamin Heidrich; Steffen B. Wiegand; ... **Ralph Link**; Uwe Naumann; et al.*
PLOS ONE October 2014 / Volume 9 / Issue 10 / e108751
54. Respiratory Complications in Outpatient Endoscopy with Endoscopist-Directed Sedation.
*Kilian Friedrich; Sabine G. Scholl; ... **Ralph Link** in bng-Study-Group; Andreas Sieg et al.*
J. Gastrointestin Liver Dis, September 2014; Vol. 23 No 3.

55. Treatment of Naive Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting; Relevance for the New Era of DAA
*Benjamin Heidrich; Steffen B. Wiegand; ... **Ralph Link**; ... Markus Cornberg, et al.*
PLOS ONE October 2014 / Volume 9 / Issue 10 / e108751
56. Treatment of patients with hepatitis C virus (HCV) genotype 3 infection in the era of direct acting antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R)
*Markus Cornberg, Peter Buggisch, ... **Ralph Link**, ... et al.*
The International Liver Congress / EASL 2016, und 13. Kongress für Infektionskrankheiten und Tropenmedizin
Juni 2016.
57. Outcomes and costs of treating hepatitis C patients in the era of first generation protease inhibitors-Results from the PAN study.
*J.T. Stahmeyer, S. Rossol, ... **R.Link**, Ch. Krauth et al*
Journal of Viral Hepatitis 2016
58. First time use of PRISM, an easy to use and suitable tool to characterize burden of disease, in patients suffering from chronic hepatitis C: Results from the German observational study LIFE-C
*M. R. Kraus; P. Buggisch; ... **R. Link**, ... , J.Hülßenbeck, et al.*
Presented at the 2017, GASL Annual Meeting, January 2017
59. Real-world effectiveness and safety of Ombitasvir, Paritaprevir/r ± Dasabuvir ± Ribavirin in patients receiving opiate substitution therapy: Results from the German observational study LIFE-C
*G. Teuber; P. Buggisch; ... **R. Link**; ... , M.R. Kraus, et. al*
Presented at the 2017 International Liver Congress, April 19-23, 2017, Amsterdam, Netherlands
Presented at the Deutsch-Österreichischer AIDS Kongress, June 14-17, 2017 Salzburg, Austria
60. Effectiveness, safety and quality of life in patients treated with Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin under real-life conditions-data from the German observational study LIFE-C
*P. Buggisch, U.Naumann, **R.Link**, ... et al.*
International Liver Congress, EASL, April 2017, Amsterdam, The Netherlands
Presented at the Deutsch-Österreichischer AIDS Kongress, June 14-17, 2017 Salzburg, Austria
61. Quality of life in HCV patients treated with Ombitasvir/ Paritaprevir/r ± Dasabuvir ± Ribavirin under Real-Life conditions-data from the German Observational study LIFE-C
*P. Buggisch; **R. Link**; U. Naumann; ... et al.*
Presented at the 2017 Liver Meeting, October 20-24, 2017, Washington DC, USA
62. Verbesserung der Lebensqualität in HCV-Patienten mit Opioid-Substitutionstherapie, die mit Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin unter Alltagsbedingungen behandelt wurden: Ergebnisse aus der deutschen Beobachtungsstudie LIFE-C
*G. Teuber; P. Buggisch; ... **R. Link**; ... et al.*
Präsentiert auf dem 26. Kongress der Deutschen Gesellschaft für Suchtmedizin, 03.-05. November 2017, Berlin, Deutschland
63. Real world use, effectiveness and safety of antiviral treatment in chronic hepatitis C genotype 3 infection: Results of the Germany Hepatitis C Registry
*Markus Cornberg; Jörg Petersen; ... **Ralph Link**; ... et al.*
Alimentary Pharmacology and Therapeutics 2017
2016 AASLD, Annual Meeting

64. Clinical management of prescribed co-medication in patients treated with ombitasvir/paritaprevir/r ± dasabuvir ± ribavirin: data from the German observational study Life-C
Buggisch P.; Link R.; Naumann U.; ... et al.
Presented at the 34th Annual Meeting of the German Association for the Study of the liver (GASL), January 26-27, 2018, Hamburg, Germany
65. Quality of life in HCV Patients treated with Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin under Real-Life Conditions-Data from the German Observational Study Life-C
P. Buggisch; R. Link; U. Naumann; ... et al.
Presented at the 34. Annual meeting of the German Association for the Study of the liver (GASL) 2018, January 26-27, Hamburg, Germany
66. Improvement of Patient Reported Outcomes in Patients under Opioid Substitution Therapy Treated for chronic Hepatitis C Infection with direct acting antivirals
Teuber G.; Buggisch P.; ... Link R.; ... et al.
67. Improvement of clinical symptoms and Patient-Reported outcomes (pro) after HCV therapy with DAA in patients on Opioid Substitution therapy (OST) – Data from the German Hepatitis C-Registry (DHC-R)
Stefan Christensen; Uwe Naumann; Ralph Link; ... et al.
The Liver Meeting der AASLD, San Francisco, November 2018
68. Improvement of Quality of Life in HCV patients receiving opiate substitution therapy treated with Ombitasvir, Paritaprevir/r ± Dasabuvir ± Ribavirin in daily practice: Results from the German observational study Life-C
Teuber G.; Buggisch P.; ... Link R.; ... et al.
69. Clinically important changes in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a large real-world setting – results from German Hepatitis C-Registry (DHC-R)
Valerie Ohlendorf; Arne Schäfer; Stefan Christensen; Renate Heyne; Uwe Naumann; Ralph Link; ... et al.
The Liver Meeting Digital Experience, AASLD; Nov. 13-16 2020
70. Weight gain after interferon-free clearance of chronic hepatitis C – Results from the German Hepatitis C-Registry (DHC-R)
Bernhard Schlegel; Klaus H.W. Boeker; ... Ralph Link; ... et al.
Abstract; International Liver Congress 2019, Vienna; April 10-14
Biomedicine journal of 2021, 9, 1495
71. Versorgungsprobleme von Patienten mit chronischer Hepatitis C während der COVID-19-Pandemie und der Lockdown-Verordnungen.
Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany.
Dieter Hüppe; Claus Niederau; Yvonne Serfert für das DHC-R
Z. Gastroenterol 2020; 58; 1182-1185
72. Influence of gender on cytokine induced depression and treatment
Schäfer Martin; Susanne Sarkar; Jonas Kemper; ... Ralph Link; ... et al.
Journal of Affective Disorders; JAFD-D-20-01022R1
73. Health related quality of life of patients in opioid substitution therapy at the beginning of hepatitis C treatment - Data from the German hepatitis C-registry (DHC-R)
Specka M; Christensen S; Buggisch P; ... ; Link R.; ... et al.
74. Improvement of clinical Symptoms and Patient-Reported outcomes (PRO) after HCV therapy with DAA in Patients on opioid Substitution therapy (OST) – Data from the German Hepatitis C-Registry (DHC-R)
Stefan Christensen; Uwe Naumann; Ralph Link; Renate Heyne; ... et al.
The Liver Meeting 2018, San Francisco, November 9-13

75. Effects on health-related quality of life on interferon-free antiviral therapy for chronic hepatitis C infection- Results from the German Hepatitis C-Registry (DHC-R)
Arne Schäfer; Stefan Christensen; Renate Heyne, Uwe Naumann; Ralph Link; ... et al.
International Liver Congress; Vienna; April 10-14 2020
76. Efficacy and safety of peginterferon alfa-2a or -2b plus Ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: The PRACTICE Study
T. Witthoef; D. Hueppe; C. John; ... R.Link; ... et al.
G. Viral Hepatitis; S315/840
77. Behandlung der chronischen Hepatitis-C-Virusinfektion vom Gentyp 3 mit direct antiviralen Substanzen: Daten aus dem Deutschen Hepatitis C-Register (DHC-R)
Cornberg M; Buggisch P; Schober A; ... Link R; ... et al.
Z. Gastroenterol 2016; 54; 799-982
78. Estimating the likelihood of Sustained Virological Response in Chronic Hepatitis C (cHC) Therapy
Stefan Mauss; Dietrich Hueppe; Christine John; ... Ralph Link; ... et al.
AASLD Abstracts A-829
79. Clinical Markers of the metabolic Syndrome are associated with HCV Genotype 1 Infection and are strong negative Predictors of early virological Response.
E. Jaeckel; E. Zehnter; C. John; ... R.Link; ... et al.
Journal of Hepatology 2010 Vol 52; S59-S182
80. Triple therapy with boceprevir plus peginterferon alpha-2a/ribavirin in a real-life setting: Is it possible to achieve SVR rates comparable to pivotal trials?
Peter Buggisch; Andreas Schober; ... Ralph Link; ... et al.
The International Liver Congress; EASL 2014, Abstract London; April: 9-13
81. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting – results from the German Hepatitis C-Register (DHC-R)
Valerie Ohlendorf; Arne Schäfer; Stefan Christensen; ... ; Ralph Link; ...Michael R. Kraus; et al.
Journal of Viral Hepatitis 2021;28:1206-1218
82. Influence of gender on cytokine induced depression and treatment Gender aspects of IFN-Alpha-induced depression.
Susanne Sarkar; Jonas Kemper; ... ; Ralph Link; ... Thomas Berg; Martin Schaefer; et al.
Journal of Affective Disorders 292 (2021) 766-772
83. Identifying persisting liver disease and liver associated morbidity and mortality after viral cure of HCV – Data from the German Hepatitis-C-Register (DHC-R)
Stefan Mauss; Hartwig Klinker; ... ; Ralph Link;... et al.
Poster presentation at The Liver Meeting November 12-15, 2021 No. 995
84. Elevated gamma-GT levels after DAA treatment indicates liver related morbidity and death despite viral cure of hepatitis C: Data from the German Hepatitis C-register (DHC-R)
Journal JHEP Reports, ILC 2022
85. Post-treatment elevated gamma-glutamyl transferase is the best predictor of future outcomes in HCV patients achieving sustained virological response- Data from the German Hepatitis C-Registry (DHC-R)
Stefan Mauss; Hartwig Klinker; Klaus HW Boeker; ... Ralph Link; Peter Buggische; ... et al.
International Liver Congress, 22-26 June 2022, Abstract #397

86. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C – Results from the German Hepatitis C- Register (DHC-R)
*Bernhard Schlevogt, Klaus H-W. Boeker, Stefan Mauss, ... **Ralph Link**, Karl-Georg Simon, ... et al.*
Biomedicines 2021, 9, 1495
Journal of Biology
4th Intern. Conference on Applied Microbiology and Beneficial Microbes, Nov. 07-08, 2022 Paris
87. Das Deutsche Hepatitis C-Register 8 Jahre nach Gründung – eine Zwischenbilanz
Dieter Hüppe; Yvonne Serfert; Albrecht Stoehr, Klaus H.W. Boeker; Ralph Link; Heiner Wedemeyer; et al.

Stand: 06.01.2023
gez: Dr. Ralph Link